AstraZeneca's Imfinzi Fails to Boost Survival in Cervical Cancer

AstraZeneca's cancer drug imfinzi failed to achieve the primary endpoint in the Phase III CALLA trial for patients with locally advanced cervical cancer.

In a statement issued Thursday, the company shared that using imfinzi (durvalumab) alongside chemoradiotherapy did not meet statistical significance in improving progression-free survival versus using CRT alone in the 770 patients who participated in the study.